J Korean Med Sci.  2011 May;26(5):697-700. 10.3346/jkms.2011.26.5.697.

Extracellular High-Mobility Group Box 1 is Increased in Patients with Behcet's Disease with Intestinal Involvement

• Ahn JK
• Cha HS
• Bae EK
• Lee J
• Koh EM

• KMID: 1777874
• DOI: http://doi.org/10.3346/jkms.2011.26.5.697

Abstract

High-mobility group box 1 (HMGB1) protein has been demonstrated to play an important role in chronic inflammatory diseases including rheumatoid arthritis, and systemic lupus erythematosus. This study investigated the association between extracellular HMGB1 expression and disease activity, and clinical features of Behcet's disease (BD). Extracellular HMGB1 expression in the sera of 42 BD patients was measured and was compared to that of 22 age- and sex-matched healthy controls. HMGB1 expression was significantly increased in BD patients compared to healthy controls (78.70 +/- 20.22 vs 10.79 +/- 1.90 ng/mL, P = 0.002). In addition, HMGB1 expression was significantly elevated in BD patients with intestinal involvement compared to those without (179.61 +/- 67.95 vs 61.89 +/- 19.81 ng/mL, P = 0.04). No significant association was observed between HMGB1 concentration and other clinical manifestations, or disease activity. It is suggested that extracellular HMGB1 may play an important role in the pathogenesis of BD.

Keyword

Behcet's disease; HMGB1 Protein; Intestinal Involvement

MeSH Terms

Adult
Aged
Behcet Syndrome/genetics/*metabolism/pathology
Extracellular Space/metabolism
Female
HMGB1 Protein/genetics/*metabolism
Humans
Inflammation
Intestinal Diseases/blood/genetics
Male
Middle Aged
Young Adult

Figure

• 

  Fig. 1 Comparison of extracellular HMGB1 levels between BD patients and healthy controls (A), and between active and inactive BD groups (B).

Reference

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999. 341:1284–1291.

2. Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, Kim WH. The prevalence and clinical characteristics of esophageal involvement in patients with Behçet's disease: a single center experience in Korea. J Korean Med Sci. 2009. 24:52–56.

3. Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001. 60:996–1002.

4. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007. 3:148–155.

5. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005. 5:331–342.

6. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta. 2010. 1799:141–148.

7. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, Chiorazzi N, Tracey KJ, Andersson U, Harris HE. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002. 46:2598–2603.

8. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003. 48:971–981.

9. Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, Lundberg IE. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 2004. 50:1586–1594.

10. Jiang W, Pisetsky DS. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis. 2008. 67:727–728.

11. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus Erythematosus: its role in cutaneous lesions development. Autoimmun Rev. 2010. 9:661–665.

12. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther. 2008. 10:209.

13. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet. 1990. 335:1078–1080.

14. Turkoz Y, Evereklioglu C, Ozkiris A, Mistik S, Borlu M, Ozerol IH, Duygulu F, Ilhan O. Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behçet's syndrome. Mediators Inflamm. 2005. 2005:237–241.

15. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 2003. 284:C870–C879.

16. Zouboulis CC, May T. Pathogenesis of Adamantiades-Behçet's disease. Adv Exp Med Biol. 2003. 528:161–171.

17. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology. 2002. 123:790–802.

18. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000. 192:565–570.

19. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003. 198:1507–1515.

20. Jung YS, Kim SW, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, Kim WH, Cheon JH. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behçet's disease. Inflamm Bowel Dis. 2011. doi: 10.1002/ibd.21600.